uploads/2018/09/Chart-005-3-1.jpg

Eli Lilly’s Market Cap and Shareholding Pattern

By

Updated

Market cap

Eli Lilly and Company’s (LLY) market cap is ~$106.0 billion as of September 26. Competitors Allergan (AGN), AstraZeneca (AZN), and AbbVie (ABBV) have market caps of ~$64.4 billion, ~$97.8 billion, and ~$142.5 billion, respectively, as of September 26.

The above chart compares the market caps of Eli Lilly and its peers.

Article continues below advertisement

Shareholding pattern

Eli Lilly has ~1.074 billion shares outstanding. Of these shares, the company’s free-floating shares total ~1.071 billion, nearly 99.75% of its total outstanding shares. Institutions hold ~79.12% of its total shares, while strategic entities own ~0.25% of its total shares.

As per its latest filing, the Lilly Endowment is Eli Lilly’s largest shareholder. The Lilly Endowment holds ~119.79 million shares, nearly 11.15% of its total shares, as of June 30. The total number of shares held by the Lilly Endowment decreased ~0.18 million in the second quarter.

The Vanguard Group holds ~73.62 million LLY shares, nearly 6.85% of its total shares, as of June 30. The total number of shares held by the Vanguard Group increased ~0.59 million in the second quarter.

The Wellington Management Company holds ~55.25 million LLY shares, nearly 5.14% of total shares, as of June 30. The total number of shares held by the Wellington Management Company decreased ~0.32 million in the second quarter.

LLY’s top ten shareholders are holding nearly 43.20% of its total outstanding shares.

The iShares Evolved US Innovative Healthcare ETF (IEIH) holds 5.4% of its total investments in Eli Lilly, 6.1% in Merck & Co. (MRK), 7.1% in Pfizer (PFE), and 9.7% in Johnson & Johnson (JNJ).

Advertisement

More From Market Realist